m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00935)
Name
6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine
Synonyms
101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H11N5O2
InChI
1S/C11H11N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,12,13,14,15)
InChIKey
MBQPVHNJEDDVCF-UHFFFAOYSA-N
PubChem CID
181029
TTD Drug ID
D04RNU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
O-6-methylguanine-DNA-alkyltransferase (MGMT)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). [1], [2]
References
Ref 1 METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner. Front Oncol. 2021 Jul 15;11:702983. doi: 10.3389/fonc.2021.702983. eCollection 2021.
Ref 2 Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. doi: 10.1200/JCO.2008.18.8417. Epub 2009 Feb 9.